Sign in

    Emma Seymour

    Research Analyst at Leerink Partners

    Emma Seymour is an Associate at Arthur Ventures, specializing in investments across healthcare, pharma services, and healthcare IT sectors. With a background in supporting M&A transactions for middle-market healthcare companies at Piper Sandler, she brings significant transactional experience to her role. She began her career after graduating from Tufts University with a degree in International Relations and French, and joined Arthur Ventures in 2025 following her tenure as an Investment Banking Associate at Piper Sandler. Seymour's foundational credentials reflect deep analytical expertise, though specific FINRA registrations or analyst performance metrics have not been publicly documented.

    Emma Seymour's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership

    Emma Seymour's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership • Q4 2024

    Question

    Emma Seymour of Piper Sandler inquired about the best-case and base-case scenarios for the Phase III AFFIRM-AL trial's primary and secondary endpoints for birtamimab, and requested more detail on the commercial opportunity in AL amyloidosis.

    Answer

    President and CEO Gene G. Kinney stated that achieving the FDA Special Protocol Assessment (SPA) success criteria of a p-value at or below 0.10 would represent a best-case scenario, given the significant unmet need for a therapy that improves survival. COO Brandon Smith added that birtamimab targets an established, multi-billion dollar global market with a consolidated prescriber base, expecting strong uptake due to its potential to demonstrate an early survival benefit.

    Ask Fintool Equity Research AI

    Emma Seymour's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership • Q4 2024

    Question

    Emma Seymour of Piper Sandler inquired about the best-case and base-case scenarios for the Phase III AFFIRM-AL trial's primary and secondary endpoints, and requested more detail on the commercial opportunity for birtamimab in AL amyloidosis.

    Answer

    President and CEO Gene G. Kinney explained that the significant unmet need in AL amyloidosis means achieving the FDA Special Protocol Assessment (SPA) success criteria of a p-value ≤ 0.10 on the all-cause mortality endpoint would represent a best-case scenario. COO Brandon Smith added that the market is established with a consolidated prescriber base, projecting birtamimab as a multi-billion dollar global opportunity due to the demand for a therapy that improves early survival.

    Ask Fintool Equity Research AI

    Emma Seymour's questions to PROTHENA CORP PUBLIC LTD (PRTA) leadership • Q4 2024

    Question

    Emma Seymour inquired about the base and best-case scenarios for the Phase III AFFIRM-AL trial's primary and key secondary endpoints for birtamimab, and asked for more detail on the commercial market opportunity in AL amyloidosis.

    Answer

    President and CEO Gene G. Kinney stated that achieving the primary endpoint with a p-value of 0.10 or less, as agreed upon with the FDA under the SPA, would represent a best-case scenario, addressing a significant unmet need in early mortality. Chief Operating Officer Brandon Smith added that the market is established, with a consolidated call point, and strong potential uptake, positioning birtamimab as a multi-billion dollar global opportunity.

    Ask Fintool Equity Research AI